

## BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent's lead candidates BI-1808 and BI-1206

TNFR2 and FcyRIIB are promising targets in immuno-oncology.

Lund, Sweden – May 24, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM ET/3-4:45 PM CEST to discuss the recently presented clinical efficacy and safety data from its lead candidates BI-1808 and BI-1206, and TNFR2 and FcyRIIB as promising targets in immuno-oncology. To register, [click here](#).

Further details on the event to be announced.

### About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at [www.bioinvent.com](http://www.bioinvent.com). Follow on the social media platform X: @BioInvent.

For further information, please contact:

Cecilia Hofvander, Senior Director Investor Relations

Phone: +46 (0)46 286 85 50

Email: [cecilia.hofvander@bioinvent.com](mailto:cecilia.hofvander@bioinvent.com)

**BioInvent International AB (publ)**

Co. Reg. No. Org nr: 556537-7263

Visiting address: Ideongatan 1

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

[www.bioinvent.com](http://www.bioinvent.com)

Press Release  
24 May 2024 15:05:00 CEST



---

## Attachments

---

[BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent's lead candidates BI-1808 and BI-1206](#)